16176-Lymphomas-Non-Hodgkins-524

Lymphomas

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

  • Details

ClinicalTrials.gov ID: NCT02947347
Diagnosis Type: Non-Hodgkins
USOR Number: 16176

  • Address

2800 Highway 75 North
Sherman, TX 75090
P: (903) 868-4700

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.